AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 14th of February ...

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $164.99 which represents a decrease of $-4.64 or -2.74% from the prior close of $169.63. The stock opened at $169.63 and touched a ...

AbbVie has rewarded shareholders again with a quarterly dividend. As a Dividend King, it is the epitome of a steady and ...

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

Shares of AbbVie Inc. ABBV shed 2.74% to $164.99 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 1.32% to 5,870.62 and Dow ...

AbbVie Inc. (ABBV) is a global biopharmaceutical company, founded in 2013 as a spinoff from Abbott Laboratories, focusing on discovering and delivering innovative medicines and solutions for ...

Shares of pharma major AbbVie Inc ($ABBV) tumbled over 12% on Monday after the company disclosed that its Schizophrenia drug ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia ...

Roopal Thakkar; Executive Vice President, Research & Development and Chief Scientific Officer; AbbVie Inc Scott Reents; Chief Financial Officer, Executive Vice President; AbbVie Inc Good morning ...